BioPharmSignal logoBioPharmSignal

Biotech News

Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

Zura Bio (ZURA)Zura BioFinancing

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 24, 2026-- Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced

Related news

MLTXMoonLake Immunotherapeutics2026-06-22 20:01 EST

MoonLake Immunotherapeutics Announces Proposed Public Offering

STTKShattuck Labs2026-06-09 20:18 EST

Shattuck Labs, Inc. Announces Proposed Public Offering

MLTXMoonLake Immunotherapeutics2026-06-24 03:08 EST

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

STTKShattuck Labs2026-06-10 04:21 EST

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

HCWBHCW Biologics2026-07-29 13:06 EST

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

ZURAZura Bio2026-08-21 23:57 EST

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CUECue Biopharma Inc2026-07-10 01:40 EST

Cue Biopharma Announces $50.0 Million Private Placement

ZURAZura Bio2026-06-29 11:30 EST

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

GRIGRI Bio2026-08-24 14:05 EST

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

SABSSAB Biotherapeutics2026-08-06 11:30 EST

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

View all latest news

Zura Bio

Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell...

Recent company news

ZURAZura Bio2026-08-21 23:57 EST

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZURAZura Bio2026-08-11 11:30 EST

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

ZURAZura Bio2026-06-29 11:30 EST

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

ZURAZura Bio2026-05-14 11:30 EST

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ZURAZura Bio2026-05-13 11:30 EST

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

Stock data

Close
5.85 USD
Market cap
389.01M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States